OAC
SPRO icon

OMERS Administration Corp’s Spero Therapeutics SPRO Stock Holding History

OMERS Administration Corp’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.2K Sell
39,400
-91,727
-70% -$218K ﹤0.01% 1026
2025
Q4 		$306K Buy
+131,127
New +$304K ﹤0.01% 812

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OMERS Administration Corp's SPRO Position: Q1 2026 in Review

OMERS Administration Corp reduced its Spero Therapeutics (SPRO) stake by 70% in Q1 2026, selling an estimated $218K and leaving 39,400 shares worth $92.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1026.

OMERS Administration Corp first reported a position in SPRO in Q4 2025 and has held it in 2 quarters since. The position peaked at $306K in Q4 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • OMERS Administration Corp held 39,400 shares of Spero Therapeutics worth $92.2K as of Q1 2026.
  • OMERS Administration Corp sold 91,727 Spero Therapeutics shares in Q1 2026, an estimated $218K.
  • Spero Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1026 holding.
  • OMERS Administration Corp first reported a position in Spero Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Spero Therapeutics position peaked at $306K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.